

Wondfo Receives Health Canada Approval for WELLlife™ COVID-19 Antigen Home Test

Rapid At-Home Identification of the COVID-19 Virus

Wondfo, a wholly owned subsidiary of Wondfo Biotech, is pleased to announce that Health Canada has granted approval for Canadian distribution of the WELLlife™ COVID-19 Antigen Home Test, an extension of our Canadian infectious disease test portfolio.

The test is designed for rapid, over-the-counter (home) use, for detection of SARS-CoV-2 infection, within five days of symptom onset. At home testing using anterior nasal samples reduces the need for doctor's office visits and prevents virus spread, while allowing physicians to provide targeted treatment.

"The addition of the WELLlife™ COVID-19 Antigen Home Test to our portfolio of Health Canada approved tests demonstrates our continued drive to provide a suite of rapid and innovative home healthcare solutions that meet critical public health needs."

— *Wingly Zhan, Senior Manager - Wondfo CA*

Wondfo is a leading international manufacturer of point-of-care tests, providing rapid diagnostic and chronic disease management solutions in four major categories including Toxicology Testing, Infectious Disease, Women's Reproductive Health, and Veterinary Diagnostics. Wondfo operates a substantive Canadian distribution center as well as boasting North American manufacturing and R&D facilities. This commitment to local manufacturing and distribution enhances Wondfo's ability to readily and reliably supply products to the Canadian market.

To learn more about the WELLlife™ COVID-19 Antigen Home Test please visit wondfousa.com.

Media Contact:

Brian Drake

Vice President, Sales and Downstream Marketing

brian.d@wondfousa.com



bringing science to life

Wondfo USA Co., Ltd.

info@wondfocanada.com

+1 (630) 468-2199 || WondfoUSA.com